CurveBeam AI Launches $1 Million SPP with $0.018 Share Price Discount
CurveBeam AI has launched a Share Purchase Plan offering eligible shareholders a 10% discount on new shares, aiming to raise up to $2 million alongside a pending $5 million placement.
- SPP offers shares at $0.018, 10% below placement price
- Target raise of $1 million, with $2 million oversubscription capacity
- Placement of $5 million subject to shareholder approval
- No brokerage or transaction fees for participants
- SPP open from 4 to 28 August 2026
Share Purchase Plan Launches at 10% Discount
CurveBeam AI Limited (ASX:CVB) has kicked off a Share Purchase Plan (SPP) allowing eligible shareholders to buy new shares at $0.018 each, a 10% discount to the $0.02 price set in a recent institutional placement. The SPP aims to raise $1 million but can scale up to $2 million if demand exceeds expectations. This move follows the company’s announcement last month of a $5 million placement to sophisticated investors, including some directors, which is still awaiting shareholder approval.
Participation Terms and Timetable
Eligible shareholders registered by the 7 July 2026 record date can apply for between $1,000 and $100,000 worth of shares under the SPP. The offer opened on 4 August and closes at 5pm AEST on 28 August, with new shares expected to be issued on 4 September and quoted on ASX from 7 September. Importantly, the SPP is not conditional on the placement’s shareholder approval, meaning it will proceed regardless of the outcome. No brokerage or transaction fees are payable by participants, and applications can be made electronically via Computershare’s platform.
Funding Strategy Amid Regulatory and Commercial Progress
This capital raising initiative comes as CurveBeam AI continues to navigate regulatory clearances and commercial partnerships in the US and China. The company’s recent strategic investment and milestone payments from WEGO Orthopaedics underpin its expansion efforts, although some regulatory approvals remain pending. The SPP and placement together represent a key funding strategy to support ongoing operations and growth ambitions in a competitive medical imaging market.
Board Discretion on Scale-Backs and Oversubscriptions
The Board retains discretion to scale back applications if the SPP is oversubscribed, ensuring the capital raise aligns with the company’s needs and shareholder interests. Eligible shareholders should carefully consider the offer documents and seek professional advice as the SPP does not account for individual financial circumstances. CurveBeam’s management has emphasised the importance of shareholder support in strengthening the company’s balance sheet ahead of anticipated regulatory milestones and commercial rollouts.
Bottom Line?
CurveBeam’s SPP offers shareholders a discounted entry point amid a broader $5 million placement, but the final capital raised hinges on shareholder participation and placement approval outcomes.
Questions in the middle?
- Will the $5 million placement secure shareholder approval at the August meeting?
- How will the combined capital raise impact CurveBeam’s cash runway and operational plans?
- What is the potential effect on share price from dilution and increased capital?
